NASDAQ:EPZM - Epizyme Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$18.45 +0.05 (+0.27 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$18.45
Today's Range$17.90 - $18.65
52-Week Range$9.30 - $21.40
Volume316,488 shs
Average Volume446,505 shs
Market Capitalization$1.26 billion
P/E Ratio-8.46
Dividend YieldN/A
Beta2

About Epizyme (NASDAQ:EPZM)

Epizyme logoEpizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL. It has collaboration agreements with Celgene Corporation, Genentech Inc., and Glaxo Group Limited, as well as with Roche Molecular Systems, Inc., Eisai Co. Ltd., and Lymphoma Study Association. Epizyme, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Receive EPZM News and Ratings via Email

Sign-up to receive the latest news and ratings for EPZM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EPZM
CUSIPN/A
Phone617-229-5872

Debt

Debt-to-Equity RatioN/A
Current Ratio10.43
Quick Ratio10.43

Price-To-Earnings

Trailing P/E Ratio-8.46
Forward P/E Ratio-8.20
P/E GrowthN/A

Sales & Book Value

Annual Sales$10 million
Price / Sales128.21
Cash FlowN/A
Price / CashN/A
Book Value$3.33 per share
Price / Book5.54

Profitability

EPS (Most Recent Fiscal Year)($2.18)
Net Income$-134,300,000.00
Net MarginsN/A
Return on Equity-61.42%
Return on Assets-50.53%

Miscellaneous

Employees131
Outstanding Shares69,490,000

Epizyme (NASDAQ:EPZM) Frequently Asked Questions

What is Epizyme's stock symbol?

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

How were Epizyme's earnings last quarter?

Epizyme Inc (NASDAQ:EPZM) posted its earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.54) by $0.05. During the same period in the prior year, the firm earned ($0.56) EPS. View Epizyme's Earnings History.

When is Epizyme's next earnings date?

Epizyme is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Epizyme.

What price target have analysts set for EPZM?

12 brokers have issued twelve-month target prices for Epizyme's shares. Their predictions range from $16.00 to $26.00. On average, they anticipate Epizyme's stock price to reach $23.00 in the next twelve months. View Analyst Ratings for Epizyme.

What are Wall Street analysts saying about Epizyme stock?

Here are some recent quotes from research analysts about Epizyme stock:
  • 1. HC Wainwright analysts commented, "We believe EPZM’s trial is no exception. As far as we know, BAP1 loss is more frequently associated with peritoneal MM while pleural MM is the most prevalent (~80%), and is also more frequently associated with MM of epitheliod origin (~88% of patients in this study). Thus, it is almost impossible to extrapolate the potential survival benefit from this specific patient group without a properly controlled, well matched placebo arm. We believe such a trial at most serves to provide depth with respect to the human PK/PD for tazemetostat, proof of concept for clinical activity and potentially to point to patient subpopulations with enriched efficacy signals." (5/21/2018)
  • 2. According to Zacks Investment Research, "Epizyme reported narrower than expected loss in the fourth quarter of 2017. Epizyme's efforts on developing its lead candidate, tazemetostat, for a number of hematological malignancies and genetically defined solid tumors are impressive. During the fourth quarter of 2017, the company had a productive interaction with the FDA to design the registration strategy for tazemetostat for epithelioid sarcomaand follicular lymphoma (FL) and identified a path to submit for accelerated approval for both the indications. The company plans to file a first new drug application of tazemetostat for epithelioid sarcoma in fourth quarter of 2018 and second NDA for FL in 2019. A potential approval for the candidate will be a significant boost for the company. So far this year, Epizyme’s share price has also outperformed the industry. However, the company is highly dependent on its collaboration partners for top-line growth with no approved product." (3/16/2018)
  • 3. Cann analysts commented, "Epizyme presented two posters at the American Society of Hematology Meeting on December 10-11, 2017. These included a biomarker study in non-Hodgkin’s lymphoma (NHL) and preliminary response data from the diffuse large B cell lymphoma (DLBCL) cohort from the ongoing phase II study of tazemetostat in NHL. The data presented is very supportive of our outlook." (12/12/2017)

Who are some of Epizyme's key competitors?

Who are Epizyme's key executives?

Epizyme's management team includes the folowing people:
  • Mr. Robert B. Bazemore Jr., Pres, CEO, Sec. & Director (Age 50)
  • Dr. H. Robert Horvitz Ph.D., M.D., Co-Founder and Chairman of the Scientific Advisory Board
  • Dr. Yi Zhang Ph.D., Scientific Co-Founder and Member of The Scientific Advisory Board
  • Mr. Matthew E. Ros, Chief Operating Officer (Age 51)
  • Dr. Michael Boretti, VP of Bus. Devel.

Has Epizyme been receiving favorable news coverage?

News headlines about EPZM stock have trended somewhat positive on Friday, Accern reports. The research firm identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Epizyme earned a media sentiment score of 0.15 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 46.47 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are Epizyme's major shareholders?

Epizyme's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Palo Alto Investors LP (9.92%), BlackRock Inc. (5.61%), Redmile Group LLC (2.90%), Rock Springs Capital Management LP (1.83%), Millennium Management LLC (1.23%) and Point72 Asset Management L.P. (1.08%). Company insiders that own Epizyme stock include Andrew E Singer, David M Mott, Matthew Ros, Peter Tai-Ching Ho and Robert A Copeland. View Institutional Ownership Trends for Epizyme.

Which institutional investors are selling Epizyme stock?

EPZM stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, BlackRock Inc., University of Notre Dame DU Lac, Citigroup Inc., Rock Springs Capital Management LP, Barclays PLC and Teacher Retirement System of Texas. Company insiders that have sold Epizyme company stock in the last year include Andrew E Singer, Matthew Ros, Peter Tai-Ching Ho and Robert A Copeland. View Insider Buying and Selling for Epizyme.

Which institutional investors are buying Epizyme stock?

EPZM stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., JPMorgan Chase & Co., UBS Group AG, Redmile Group LLC, Sio Capital Management LLC, Opaleye Management Inc., Thrivent Financial for Lutherans and Eversept Partners LLC. View Insider Buying and Selling for Epizyme.

How do I buy shares of Epizyme?

Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Epizyme's stock price today?

One share of EPZM stock can currently be purchased for approximately $18.45.

How big of a company is Epizyme?

Epizyme has a market capitalization of $1.26 billion and generates $10 million in revenue each year. The biopharmaceutical company earns $-134,300,000.00 in net income (profit) each year or ($2.18) on an earnings per share basis. Epizyme employs 131 workers across the globe.

How can I contact Epizyme?

Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected]


MarketBeat Community Rating for Epizyme (EPZM)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  313 (Vote Outperform)
Underperform Votes:  200 (Vote Underperform)
Total Votes:  513
MarketBeat's community ratings are surveys of what our community members think about Epizyme and other stocks. Vote "Outperform" if you believe EPZM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPZM will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Epizyme (NASDAQ:EPZM) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
12 Wall Street analysts have issued ratings and price targets for Epizyme in the last 12 months. Their average twelve-month price target is $23.00, suggesting that the stock has a possible upside of 24.66%. The high price target for EPZM is $26.00 and the low price target for EPZM is $16.00. There are currently 2 hold ratings and 10 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.832.832.922.90
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $23.00$22.5455$23.00$23.00
Price Target Upside: 24.66% upside73.43% upside41.98% upside37.72% upside

Epizyme (NASDAQ:EPZM) Consensus Price Target History

Price Target History for Epizyme (NASDAQ:EPZM)

Epizyme (NASDAQ:EPZM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/21/2018HC WainwrightReiterated RatingBuy$25.00LowView Rating Details
5/18/2018WedbushBoost Price Target$20.00 ➝ $25.00LowView Rating Details
4/24/2018Roth CapitalSet Price TargetBuy$24.00MediumView Rating Details
4/24/2018Leerink SwannSet Price TargetBuy$24.00HighView Rating Details
4/24/2018SunTrust BanksLower Price TargetBuy ➝ Hold$20.00HighView Rating Details
1/24/2018Jefferies GroupReiterated RatingBuy ➝ Buy$25.00LowView Rating Details
1/10/2018Morgan StanleyInitiated CoverageOverweight ➝ Overweight$20.00HighView Rating Details
12/12/2017OppenheimerSet Price TargetBuy$26.00MediumView Rating Details
12/12/2017CannReiterated RatingBuy$26.00MediumView Rating Details
11/2/2017Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$20.00 ➝ $16.00N/AView Rating Details
6/16/2017CitigroupBoost Price TargetBuy$20.00 ➝ $22.00LowView Rating Details
6/7/2017CowenReiterated RatingBuyHighView Rating Details
4/13/2017CIBCReiterated RatingOutperform ➝ OutperformLowView Rating Details
11/6/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
6/20/2016MizuhoReiterated RatingBuy$18.00N/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Epizyme (NASDAQ:EPZM) Earnings History and Estimates Chart

Earnings by Quarter for Epizyme (NASDAQ:EPZM)

Epizyme (NASDAQ:EPZM) Earnings Estimates

2018 EPS Consensus Estimate: ($2.30)
2019 EPS Consensus Estimate: ($1.53)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20185($0.56)($0.52)($0.54)
Q2 20185($0.60)($0.47)($0.53)
Q3 20185($0.91)($0.45)($0.61)
Q4 20185($1.00)($0.39)($0.61)
Q1 20191($0.39)($0.39)($0.39)
Q2 20191($0.39)($0.39)($0.39)
Q3 20191($0.39)($0.39)($0.39)
Q4 20191($0.36)($0.36)($0.36)

Epizyme (NASDAQ EPZM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2018($0.52)N/AView Earnings Details
5/8/2018Q1 2018($0.54)($0.49)$0.19 millionViewN/AView Earnings Details
3/13/2018Q4 2017($0.57)($0.52)$0.11 millionViewListenView Earnings Details
11/1/2017Q3 2017($0.65)($0.63)$0.19 millionViewN/AView Earnings Details
8/4/2017Q2 2017($0.56)($0.48)$3.95 million$10.00 millionViewN/AView Earnings Details
5/8/2017Q1 2017($0.63)($0.56)$0.49 millionViewN/AView Earnings Details
3/9/2017Q4 2016($0.65)($0.60)$0.61 million$0.48 millionViewListenView Earnings Details
11/3/2016Q3($0.60)($0.42)$0.57 million$6.58 millionViewListenView Earnings Details
8/8/2016Q2($0.52)($0.49)$0.61 million$0.47 millionViewListenView Earnings Details
5/9/2016Q1($0.53)($0.41)$0.58 million$0.47 millionViewListenView Earnings Details
3/9/2016Q415($0.65)($0.53)$0.66 million$0.56 millionViewListenView Earnings Details
11/9/2015Q315($0.59)($0.56)$8.75 million$0.36 millionViewListenView Earnings Details
8/6/2015Q215($0.70)($0.63)$2.23 million$0.74 millionViewListenView Earnings Details
4/28/2015Q115($0.99)($1.75)$6.48 million$0.91 millionViewN/AView Earnings Details
3/12/2015Q414($0.54)($0.44)$10.10 million$10.35 millionViewListenView Earnings Details
11/6/2014Q314($0.54)($0.58)$7.00 million$8.20 millionViewN/AView Earnings Details
8/13/2014Q214($0.46)($0.40)$7.59 million$9.50 millionViewN/AView Earnings Details
5/13/2014Q114($0.48)($0.22)$7.67 million$13.39 millionViewN/AView Earnings Details
2/27/2014Q413($0.22)$0.52$9.00 million$36.32 millionViewN/AView Earnings Details
10/22/2013Q3 2013($0.36)($0.34)$8.07 million$8.44 millionViewN/AView Earnings Details
7/31/2013Q2 2013($0.26)($0.25)$11.27 million$14.84 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Epizyme (NASDAQ:EPZM) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Epizyme (NASDAQ EPZM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 21.50%
Institutional Ownership Percentage: 84.82%
Insider Trading History for Epizyme (NASDAQ:EPZM)
Institutional Ownership by Quarter for Epizyme (NASDAQ:EPZM)

Epizyme (NASDAQ EPZM) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/5/2018Matthew RosCOOSell72,264$16.63$1,201,750.3274,867View SEC Filing  
10/24/2017Peter Tai-Ching HoInsiderSell15,000$16.44$246,600.0023,123View SEC Filing  
9/25/2017Peter Tai-Ching HoInsiderSell15,000$16.81$252,150.0023,123View SEC Filing  
9/18/2017David M MottDirectorBuy200,000$15.25$3,050,000.006,000View SEC Filing  
8/24/2017Peter Tai-Ching HoInsiderSell15,000$15.68$235,200.0022,228View SEC Filing  
7/24/2017Peter Tai-Ching HoInsiderSell15,000$13.44$201,600.0022,228View SEC Filing  
6/30/2017Andrew E SingerCFOSell3,024$15.50$46,872.0040,529View SEC Filing  
6/26/2017Peter Tai-Ching HoInsiderSell15,000$14.87$223,050.0022,228View SEC Filing  
6/6/2017Robert A CopelandInsiderSell2,500$13.45$33,625.0034,038View SEC Filing  
5/25/2017Peter Tai-Ching HoInsiderSell15,000$16.11$241,650.0022,228View SEC Filing  
5/2/2017Robert A CopelandInsiderSell5,000$17.44$87,200.0036,538View SEC Filing  
4/4/2017Robert A CopelandInsiderSell5,000$16.36$81,800.0033,538View SEC Filing  
3/31/2017Andrew E SingerCFOSell2,013$17.09$34,402.1736,175View SEC Filing  
1/9/2017Andrew E SingerCFOSell1,013$12.04$12,196.5233,506View SEC Filing  
12/9/2016Andrew E SingerCFOSell1,013$11.03$11,173.3932,060View SEC Filing  
11/9/2016Andrew E SingerCFOSell1,013$10.40$10,535.2030,613View SEC Filing  
10/10/2016Andrew E SingerCFOSell1,013$9.72$9,846.3629,167View SEC Filing  
9/9/2016Andrew E SingerCFOSell1,013$7.55$7,648.1527,721View SEC Filing  
8/9/2016Andrew E SingerCFOSell1,013$9.05$9,167.6526,274View SEC Filing  
8/1/2016Robert A CopelandInsiderSell4,000$10.37$41,480.0035,538View SEC Filing  
7/11/2016Andrew E SingerCFOSell1,013$10.36$10,494.6824,828View SEC Filing  
7/5/2016Robert A CopelandInsiderSell4,000$10.03$40,120.004,000View SEC Filing  
6/9/2016Andrew E SingerCFOSell1,013$12.49$12,652.3723,382View SEC Filing  
4/12/2016Andrew E SingerCFOSell1,013$12.42$12,581.4620,489View SEC Filing  
3/9/2016Andrew E SingerCFOSell1,006$9.33$9,385.9819,036View SEC Filing  
2/29/2016Peter Tai-Ching HoInsiderBuy636$7.47$4,750.92View SEC Filing  
2/10/2016Andrew E. SingerCFOSell12,158$9.54$115,987.3217,354View SEC Filing  
1/12/2016Bay City Capital Fund V Co-InvMajor ShareholderBuy555,555$9.00$4,999,995.00View SEC Filing  
1/12/2016David M MottDirectorBuy1,111,111$9.00$9,999,999.00View SEC Filing  
1/4/2016Robert A. CopelandinsiderSell4,185$15.58$65,202.30View SEC Filing  
12/30/2015Robert J. GouldDirectorSell32,108$18.01$578,265.08View SEC Filing  
12/9/2015Peter Tai-Ching HoInsiderBuy1,000$14.69$14,690.00View SEC Filing  
12/7/2015Robert A. CopelandinsiderSell4,185$13.82$57,836.70View SEC Filing  
11/9/2015Robert A. CopelandinsiderSell4,185$16.26$68,048.10View SEC Filing  
10/5/2015Robert A. CopelandinsiderSell4,185$14.43$60,389.55View SEC Filing  
9/8/2015Robert A. CopelandinsiderSell4,185$19.58$81,942.30View SEC Filing  
9/8/2015Robert J. GouldCEOSell60,000$19.86$1,191,600.00View SEC Filing  
7/6/2015Robert A CopelandInsiderSell8,371$22.86$191,361.06View SEC Filing  
7/6/2015Robert J GouldCEOSell60,000$23.22$1,393,200.00View SEC Filing  
5/5/2015Peter Tai-Ching HoInsiderBuy800$16.36$13,088.00View SEC Filing  
12/2/2014Peter Tai-Ching HoInsiderBuy1,000$21.17$21,170.00View SEC Filing  
11/17/2014Robert A CopelandEVPSell20,000$22.68$453,600.00View SEC Filing  
11/3/2014Robert A CopelandEVPSell20,000$25.47$509,400.00View SEC Filing  
11/3/2014Robert J GouldCEOSell30,000$24.95$748,500.00View SEC Filing  
10/7/2014Robert A CopelandEVPSell20,000$26.90$538,000.00View SEC Filing  
10/1/2014Robert J GouldCEOSell30,000$26.28$788,400.00View SEC Filing  
10/1/2014Stephen GarbaczInsiderSell868$27.06$23,488.08View SEC Filing  
9/22/2014Robert A CopelandEVPSell20,000$25.55$511,000.00View SEC Filing  
9/15/2014Eric HedrickInsiderSell2,000$28.67$57,340.00View SEC Filing  
9/4/2014Carl GoldfischerDirectorSell4,000$35.14$140,560.00View SEC Filing  
8/26/2014Bay City Capital LlcMajor ShareholderSell200,000$35.14$7,028,000.00View SEC Filing  
8/25/2014Bay City Capital LlcMajor ShareholderSell366,666$33.98$12,459,310.68View SEC Filing  
8/18/2014Robert A CopelandEVPSell10,830$36.07$390,638.10View SEC Filing  
8/15/2014Ryan D DrantMajor ShareholderSell4,061$36.54$148,388.94View SEC Filing  
8/4/2014Jason P RhodesCFOSell30,000$29.74$892,200.00View SEC Filing  
8/4/2014Robert A CopelandEVPSell20,000$29.42$588,400.00View SEC Filing  
7/15/2014Eric HedrickInsiderSell2,000$31.35$62,700.00View SEC Filing  
7/7/2014Jason P RhodesCFOSell30,000$32.74$982,200.00View SEC Filing  
7/1/2014Robert J GouldCEOSell30,000$31.53$945,900.00View SEC Filing  
6/23/2014Robert A CopelandEVPSell20,000$28.42$568,400.00View SEC Filing  
6/16/2014Eric HedrickInsiderSell2,000$26.42$52,840.00View SEC Filing  
6/16/2014Robert A CopelandEVPSell25,012$26.38$659,816.56View SEC Filing  
6/2/2014Robert J GouldCEOSell30,000$22.20$666,000.00View SEC Filing  
5/19/2014Robert CopelandEVPSell5,000$22.28$111,400.0017,561View SEC Filing  
5/5/2014Jason RhodesCFOSell30,000$21.53$645,900.0046,000View SEC Filing  
5/5/2014Robert CopelandEVPSell10,000$21.29$212,900.0020,011View SEC Filing  
5/1/2014Robert GouldCEOSell30,000$21.91$657,300.00View SEC Filing  
4/28/2014Robert CopelandEVPSell13,800$20.73$286,074.0024,911View SEC Filing  
4/7/2014Jason RhodesCFOSell25,000$20.05$501,250.0034,000View SEC Filing  
4/7/2014Robert GouldCEOSell30,000$20.22$606,600.00View SEC Filing  
2/10/2014Celgene European Investment Comajor shareholderBuy340,000$29.25$9,945,000.00View SEC Filing  
1/6/2014Jason RhodesCFOSell10,000$20.19$201,900.004,000View SEC Filing  
12/16/2013Robert CopelandEVPSell4,600$21.21$97,566.0053,544View SEC Filing  
12/2/2013Robert CopelandEVPSell5,000$20.70$103,500.0053,544View SEC Filing  
11/15/2013M James Barrettmajor shareholderBuy406,500$19.68$7,999,920.00View SEC Filing  
6/5/2013David M MottDirectorBuy400,000$15.00$6,000,000.00View SEC Filing  
6/5/2013Venture Fund I L.P. AstellasMajor ShareholderBuy15,333$15.00$229,995.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Epizyme (NASDAQ EPZM) News Headlines

Source:
DateHeadline
Epizyme Inc (EPZM) Given Consensus Recommendation of "Buy" by BrokeragesEpizyme Inc (EPZM) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 25 at 3:32 AM
Epizyme (EPZM) Stock Rating Reaffirmed by HC WainwrightEpizyme (EPZM) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - May 21 at 11:06 AM
Blog Exposure - BeiGene Commenced Phase-3 Trial of Pamiparib in ChinaBlog Exposure - BeiGene Commenced Phase-3 Trial of Pamiparib in China
finance.yahoo.com - May 21 at 8:41 AM
Epizyme (EPZM) Price Target Raised to $25.00 at WedbushEpizyme (EPZM) Price Target Raised to $25.00 at Wedbush
www.americanbankingnews.com - May 18 at 5:13 PM
Epizyme (EPZM) to Present New Tazemetostat Data at ASCO and EHAEpizyme (EPZM) to Present New Tazemetostat Data at ASCO and EHA
www.streetinsider.com - May 17 at 5:36 PM
Epizyme to Present New Tazemetostat Data at the American Society of Clinical Oncology (ASCO) Annual Meeting and ...Epizyme to Present New Tazemetostat Data at the American Society of Clinical Oncology (ASCO) Annual Meeting and ...
globenewswire.com - May 17 at 5:36 PM
Epizyme to Present New Tazemetostat Data at the American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) CongressEpizyme to Present New Tazemetostat Data at the American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) Congress
finance.yahoo.com - May 17 at 5:36 PM
Epizyme Expected to Post Q2 2018 Earnings of ($0.47) Per Share (EPZM)Epizyme Expected to Post Q2 2018 Earnings of ($0.47) Per Share (EPZM)
www.americanbankingnews.com - May 11 at 8:54 AM
SunTrust Banks Comments on Epizymes Q2 2018 Earnings (EPZM)SunTrust Banks Comments on Epizyme's Q2 2018 Earnings (EPZM)
www.americanbankingnews.com - May 11 at 8:54 AM
Oppenheimer Comments on Epizymes Q2 2018 Earnings (EPZM)Oppenheimer Comments on Epizyme's Q2 2018 Earnings (EPZM)
www.americanbankingnews.com - May 11 at 8:54 AM
Epizyme (EPZM) to Post Q2 2018 Earnings of ($0.52) Per Share, Jefferies Group ForecastsEpizyme (EPZM) to Post Q2 2018 Earnings of ($0.52) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - May 11 at 8:54 AM
Epizyme (EPZM) Expected to Announce Quarterly Sales of $2.17 MillionEpizyme (EPZM) Expected to Announce Quarterly Sales of $2.17 Million
www.americanbankingnews.com - May 11 at 2:56 AM
Epizyme (EPZM) Upgraded by ValuEngine to SellEpizyme (EPZM) Upgraded by ValuEngine to Sell
www.americanbankingnews.com - May 10 at 12:47 PM
Epizyme Expected to Post Q1 2019 Earnings of ($0.39) Per Share (EPZM)Epizyme Expected to Post Q1 2019 Earnings of ($0.39) Per Share (EPZM)
www.americanbankingnews.com - May 10 at 8:52 AM
Epizyme to Post Q2 2018 Earnings of ($0.55) Per Share, Leerink Swann Forecasts (EPZM)Epizyme to Post Q2 2018 Earnings of ($0.55) Per Share, Leerink Swann Forecasts (EPZM)
www.americanbankingnews.com - May 10 at 6:54 AM
Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q1Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q1
finance.yahoo.com - May 9 at 5:06 PM
Zacks: Analysts Expect Epizyme (EPZM) Will Announce Earnings of -$0.57 Per ShareZacks: Analysts Expect Epizyme (EPZM) Will Announce Earnings of -$0.57 Per Share
www.americanbankingnews.com - May 9 at 11:26 AM
Epizyme (EPZM) Posts Quarterly  Earnings Results, Beats Estimates By $0.05 EPSEpizyme (EPZM) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS
www.americanbankingnews.com - May 8 at 12:13 PM
EPIZYME, INC.EPIZYME, INC.
www.streetinsider.com - May 8 at 8:47 AM
BRIEF-Epizyme Reports Q1 Loss Per Share Of $0.49BRIEF-Epizyme Reports Q1 Loss Per Share Of $0.49
www.reuters.com - May 8 at 8:47 AM
Epizyme Reports First Quarter 2018 Financial Results and Provides Business UpdatesEpizyme Reports First Quarter 2018 Financial Results and Provides Business Updates
finance.yahoo.com - May 8 at 8:47 AM
Epizyme Inc (NASDAQ:EPZM): Does The -21.86% Earnings Drop Reflect A Longer Term Trend?Epizyme Inc (NASDAQ:EPZM): Does The -21.86% Earnings Drop Reflect A Longer Term Trend?
finance.yahoo.com - May 8 at 8:47 AM
Epizyme: 1Q Earnings SnapshotEpizyme: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 8:47 AM
Epizyme (EPZM) Reports Narrower-than-Expected Q1 LossEpizyme (EPZM) Reports Narrower-than-Expected Q1 Loss
finance.yahoo.com - May 8 at 8:47 AM
Is a Beat in Store for Epizyme (EPZM) This Earnings Season?Is a Beat in Store for Epizyme (EPZM) This Earnings Season?
www.zacks.com - May 7 at 5:12 PM
Epizyme Announces First Quarter 2018 Financial Reporting Date and Upcoming Conference CallEpizyme Announces First Quarter 2018 Financial Reporting Date and Upcoming Conference Call
globenewswire.com - May 1 at 8:53 AM
Epizyme (EPZM) Scheduled to Post Earnings on MondayEpizyme (EPZM) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - April 30 at 9:41 AM
Epizyme (EPZM) Receives Average Recommendation of "Buy" from AnalystsEpizyme (EPZM) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 30 at 3:48 AM
FY2019 Earnings Estimate for Epizyme (EPZM) Issued By SunTrust BanksFY2019 Earnings Estimate for Epizyme (EPZM) Issued By SunTrust Banks
www.americanbankingnews.com - April 26 at 11:05 AM
FY2018 Earnings Forecast for Epizyme (EPZM) Issued By WedbushFY2018 Earnings Forecast for Epizyme (EPZM) Issued By Wedbush
www.americanbankingnews.com - April 26 at 10:24 AM
Epizyme (EPZM) PT Set at $24.00 by Roth CapitalEpizyme (EPZM) PT Set at $24.00 by Roth Capital
www.americanbankingnews.com - April 25 at 10:30 AM
Epizyme (EPZM) Rating Lowered to Strong Sell at ValuEngineEpizyme (EPZM) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - April 25 at 12:58 AM
BidaskClub Lowers Epizyme (EPZM) to HoldBidaskClub Lowers Epizyme (EPZM) to Hold
www.americanbankingnews.com - April 25 at 12:26 AM
We Expect A Quick Resolution: Despite Partial Clinical Hold On Epizymes Drug Candidate, Wedbush Stays Bullish'We Expect A Quick Resolution': Despite Partial Clinical Hold On Epizyme's Drug Candidate, Wedbush Stays Bullish
finance.yahoo.com - April 24 at 5:13 PM
Epizyme Shares Drop After Partial Clinical Hold Placed On Lead Cancer DrugEpizyme Shares Drop After Partial Clinical Hold Placed On Lead Cancer Drug
feeds.benzinga.com - April 24 at 10:49 AM
Leerink Swann Analysts Give Epizyme (EPZM) a $24.00 Price TargetLeerink Swann Analysts Give Epizyme (EPZM) a $24.00 Price Target
www.americanbankingnews.com - April 24 at 9:30 AM
Wedbush Lowers Epizyme (EPZM) Price Target to $20.00Wedbush Lowers Epizyme (EPZM) Price Target to $20.00
www.americanbankingnews.com - April 24 at 9:12 AM
SunTrust Banks Reiterates Buy Rating for Epizyme (EPZM)SunTrust Banks Reiterates Buy Rating for Epizyme (EPZM)
www.americanbankingnews.com - April 24 at 8:54 AM
PRTA Jolted, FDA Strikes Down PFEs Herceptin Biosimilar, No Relief Yet For KMDAPRTA Jolted, FDA Strikes Down PFE's Herceptin Biosimilar, No Relief Yet For KMDA
www.nasdaq.com - April 24 at 8:45 AM
US STOCKS ON THE MOVE-Incyte, Epizyme, Shire, ValeritasUS STOCKS ON THE MOVE-Incyte, Epizyme, Shire, Valeritas
www.nasdaq.com - April 24 at 8:45 AM
Biotech Analysis Central Pharma News: Orexigens Last Resort, Epizymes Partial Clinical Hold, Eli Lilly And Incytes ...Biotech Analysis Central Pharma News: Orexigen's Last Resort, Epizyme's Partial Clinical Hold, Eli Lilly And Incyte's ...
seekingalpha.com - April 24 at 8:45 AM
$750,000.00 in Sales Expected for Epizyme (EPZM) This Quarter$750,000.00 in Sales Expected for Epizyme (EPZM) This Quarter
www.americanbankingnews.com - April 24 at 4:48 AM
Epizyme (EPZM) Says US-based Enrollment of New Patients into Tazemetostat Clinical Trials is Temporarily on HoldEpizyme (EPZM) Says US-based Enrollment of New Patients into Tazemetostat Clinical Trials is Temporarily on Hold
www.streetinsider.com - April 23 at 4:54 PM
Epizyme Provides Update Regarding Tazemetostat Clinical ProgramEpizyme Provides Update Regarding Tazemetostat Clinical Program
finance.yahoo.com - April 23 at 4:54 PM
-$0.54 Earnings Per Share Expected for Epizyme (EPZM) This Quarter-$0.54 Earnings Per Share Expected for Epizyme (EPZM) This Quarter
www.americanbankingnews.com - April 22 at 3:08 AM
Why Is Epizyme (EPZM) Down 18% Since Its Last Earnings Report?Why Is Epizyme (EPZM) Down 18% Since Its Last Earnings Report?
www.zacks.com - April 12 at 9:26 AM
Epizymes (EPZM) "Buy" Rating Reiterated at HC WainwrightEpizyme's (EPZM) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - April 12 at 12:29 AM
Epizyme (EPZM) Publishes Tazemetostat Phase I Data, Stock UpEpizyme (EPZM) Publishes Tazemetostat Phase I Data, Stock Up
finance.yahoo.com - April 11 at 5:03 PM
Epizyme (EPZM) Reports Publication of Tazemetostat Phase 1 Clinical Data in The Lancet OncologyEpizyme (EPZM) Reports Publication of Tazemetostat Phase 1 Clinical Data in The Lancet Oncology
www.streetinsider.com - April 10 at 5:05 PM
Epizyme (EPZM) Downgraded to "Hold" at BidaskClubEpizyme (EPZM) Downgraded to "Hold" at BidaskClub
www.americanbankingnews.com - April 10 at 10:25 AM

SEC Filings

Epizyme (NASDAQ:EPZM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Epizyme (NASDAQ:EPZM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Epizyme (NASDAQ EPZM) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.